HFL ENTERPRISES, LLC – Trademark Portfolio
Entity Type: 16
HFL ENTERPRISES, LLC holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 5 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 3 Nice Classification classes. Currently, 9 trademarks are registered. Notable registered marks include LAC, SPL, DGST, THERA-ZYME, and LOOMIS SYSTEM. The owner is based in MADISON, WI.
6421 ENTERPRISE LANE
MADISON, WI 53719
Showing of trademarks Trademarks
Trademark Classifications
HFL ENTERPRISES, LLC's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does HFL ENTERPRISES, LLC have?
HFL ENTERPRISES, LLC has 10 U.S. trademarks filed with the USPTO. Of these, 9 registered, 1 cancelled.
What trademark classes does HFL ENTERPRISES, LLC file in?
HFL ENTERPRISES, LLC files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are HFL ENTERPRISES, LLC's most well-known trademarks?
HFL ENTERPRISES, LLC's registered trademark portfolio includes well-known marks such as LAC, SPL, DGST, THERA-ZYME, and LOOMIS SYSTEM. These are among 9 currently registered trademarks in the portfolio.
What is HFL ENTERPRISES, LLC's trademark registration success rate?
HFL ENTERPRISES, LLC has a 90% trademark registration rate, with 9 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.